Company Overview and News

0
Patanjali seeks more info on Adani#39;s bid on Ruchi Soya

14h moneycontrol
Baba Ramdev's Patanjali Group, which is in race to acquire bankruptcy-bound Ruchi Soya, has sought more information related to the bid submitted by its rival Adani Group and also on appointment of a legal advisor of the resolution professional.
RUCHISOYA 500368

0
Patanjali seeks more info on Adani’s bid on Ruchi Soya

15h livemint
New Delhi: Baba Ramdev’s Patanjali Ayurved, which is in race to acquire bankruptcy-bound Ruchi Soya, has sought more information related to the bid submitted by its rival Adani Group and also on appointment of a legal adviser of the resolution professional.
RUCHISOYA 500368

0
Patanjali seeks more info on Adani#39;s bid on Ruhi Soya

2018-06-18 moneycontrol
Baba Ramdev's Patanjali Group, which is in race to acquire bankruptcy-bound Ruchi Soya, has sought more information related to the bid submitted by its rival Adani Group and also on appointment of a legal advisor of the resolution professional.
RUCHISOYA 500368

0
Ruchi Soya Industries Limited - Updates

2018-06-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RUCHISOYA 500368

0
Ruchi Soya Industries Limited - Updates

2018-06-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RUCHISOYA 500368

0
Ruch Soya hits upper price limit

2018-06-14 thehindubusinessline
Shares of edible oil producer Ruchi Soya Industries Ltd climbed as much as 4.7 per cent to hit their upper price limit at Rs 13.35 as the company had said on Wednesday that its committee of lenders had declared Adani Wilmar Ltd as the highest bidder, and Patanjali Ayurveda-led consortium as second-highest bidder.
OBZIY OBEROIRLTY RUCHISOYA 533273 500368

0
Ruchi Soya Industries Limited - News Verification

2018-06-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RUCHISOYA 500368

8
Sensex ends mildly higher amid volatile moves, Nifty above 10,850-mark; pharma gains big

2018-06-13 moneycontrol
Some selling pressure gripped the market in the last hour of trade as investors may have turned cautious ahead of US Federal Reserve’s policy meet decision later in the day.
PGDQY PAGEIND RCOM RUCHISOYA 532827 IDEA ICLQY 500368 532712 500493 532822 BHARATFORG

0
Ruchi Soya locked at 5% upper circuit after Adani emerges as top bidder

2018-06-13 moneycontrol
Shares of Ruchi Soya Industries locked at 5 percent upper circuit as Adani group emerged as highest bidder for the company.
RUCHISOYA 500368

0
Ruchi Soya Industries Limited - News Verification

2018-06-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RUCHISOYA 500368

0
Adani group firm offers Rs6,000 crore for Ruchi Soya

2018-06-12 livemint
New Delhi: Billionaire Gautam Adani’s group company on Tuesday offered about ₹6,000 crore to emerge as the highest bidder for acquisition of bankruptcy-hit edible oil firm Ruchi Soya, people with direct knowledge of the matter said.
RUCHISOYA 500368

0
Gautam Adani group emerges as highest bidder with Rs 6,000 cr offer for Ruchi Soya

2018-06-12 freepressjournal.in
New Delhi: Billionaire Gautam Adani’s group company today offered about Rs 6,000 crore to emerge as the highest bidder for acquisition of bankruptcy-hit edible oil firm Ruchi Soya, sources with direct knowledge of the matter said. Baba Ramdev-promoted Patanjali Ayurved, the only other qualified player in the race, has bid for around Rs 5,700 crore, they added.
RUCHISOYA 500368

0
Patanjali, Adani submit revised bids to acquire Ruchi Soya

2018-06-11 moneycontrol
Baba Ramdev-promoted Patanjali Ayurved and Adani group today submitted their revised bids to acquire to bankruptcy-hit firm Ruchi Soya as lenders of the edible oil firm have decided to hold a fresh round of resolution process to maximise asset value, said sources. The Committee of Creditors (CoC) of Ruchi Soya, which has decided to conduct Swiss challenge method to maximise the asset value of the bankruptcy-hit firm, is expected to open the bids tomorrow, they added.
532179 CRPKY RUCHISOYA 500368 CORPBANK

0
Patanjali to submit revised bid on June 11 to acquire Ruchi Soya

2018-06-10 moneycontrol
Baba Ramdev-promoted Patanjali Ayurved, which is in the race with Adani group to acquire bankruptcy-hit Ruchi Soya, is likely to submit a revised bid on June 11 as lenders of the edible oil firm have decided to hold a fresh round of resolution process between the two contenders to maximise asset value.
532179 CRPKY RUCHISOYA 500368 CORPBANK

0
Ruchi Soya Industries Limited - Financial Result Updates

2018-06-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RUCHISOYA 500368

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...